Back to top
more

Becton, Dickinson and Company (BDX)

(Real Time Quote from BATS)

$156.45 USD

156.45
200,920

-0.64 (-0.41%)

Updated Apr 9, 2026 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 244)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.

Zacks Equity Research

Becton, Dickinson (BDX) a Step Closer to Bard Acquisition

by Zacks Equity Research

Becton, Dickinson and Company (BDX) gets FTC's nod for the acquisition of C. R. Bard.

    Zacks Equity Research

    Merit Medical Deserves a Place in Your Portfolio: Here's Why

    by Zacks Equity Research

    A slew of bolt-on acquisitions leverages Merit Medical (MMSI) to drive inorganic growth.

      Zacks Equity Research

      The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Morris, EOG Resources, Becton, Dickinson, Sirius XM and ABB

        Zacks Equity Research

        Becton, Dickinson Banks on Bard Buyout, Medical Unit Weak

        by Zacks Equity Research

        Becton, Dickinson (BDX) is steadily progressing with the acquisition of C. R. Bard. However, sluggishness in the Medical Segment is a headwind.

          Zacks Equity Research

          Becton, Dickinson Focuses on Medication Management, Stock Up

          by Zacks Equity Research

          Management at Becton, Dickinson and Company (BDX) has been focusing on strengthening its portfolio for long.

            Zacks Equity Research

            Becton Dickinson (BDX) in Focus: Stock Moves 7.7% Higher

            by Zacks Equity Research

            Becton Dickinson (BDX) saw its shares rise nearly 8% on the day after the company posted better-than-expected third-quarter results.

              Zacks Equity Research

              Becton (BDX) Tops Q4 Earnings and Revenues Estimates

              by Zacks Equity Research

              Becton, Dickinson???s adjusted earnings of $2.40 per share beat the Zacks Consensus Estimate by 2 cents and increased from $2.12 posted in the year-ago quarter.

                Zacks Equity Research

                Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?

                by Zacks Equity Research

                Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.

                  Zacks Equity Research

                  Becton, Dickinson (BDX) Tops Q3 Earnings, Misses On Revenues

                  by Zacks Equity Research

                  Impressive results in Becton, Dickinson's (BDX) medical segment reflect strong performance in the Medication and Procedural Solutions, Diabetes Care and Pharmaceutical Systems units.

                    Zacks Equity Research

                    Becton, Dickinson (BDX) Q2 Earnings: What's in the Cards?

                    by Zacks Equity Research

                    Becton, Dickinson's (BDX) second-quarter performance faces risks from unfavorable foreign exchange rate.